256 related articles for article (PubMed ID: 28060011)
1. Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis.
Makarova N; Henning T; Taylor A; Dinh C; Lipscomb J; Aubert R; Hanson D; Phillips C; Papp J; Mitchell J; McNicholl J; Garcia-Lerma GJ; Heneine W; Kersh E; Dobard C
AIDS; 2017 Mar; 31(6):745-752. PubMed ID: 28060011
[TBL] [Abstract][Full Text] [Related]
2. Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.
Radzio J; Henning T; Jenkins L; Ellis S; Farshy C; Phillips C; Holder A; Kuklenyik S; Dinh C; Hanson D; McNicholl J; Heneine W; Papp J; Kersh EN; García-Lerma JG
J Infect Dis; 2016 May; 213(10):1541-5. PubMed ID: 26743846
[TBL] [Abstract][Full Text] [Related]
3. Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis.
Henning TR; Butler K; Hanson D; Sturdevant G; Ellis S; Sweeney EM; Mitchell J; Deyounks F; Phillips C; Farshy C; Fakile Y; Papp J; Evan Secor W; Caldwell H; Patton D; McNicholl JM; Kersh E
J Infect Dis; 2014 Oct; 210(8):1239-47. PubMed ID: 24755433
[TBL] [Abstract][Full Text] [Related]
4. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
6. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
7. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
[TBL] [Abstract][Full Text] [Related]
8. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3).
Henning T; Fakile Y; Phillips C; Sweeney E; Mitchell J; Patton D; Sturdevant G; Caldwell HD; Secor WE; Papp J; Hendry RM; McNicholl J; Kersh E
J Med Primatol; 2011 Aug; 40(4):214-23. PubMed ID: 21781129
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques.
Dobard CW; Makarova N; West-Deadwyler R; Taylor A; Dinh C; Martin A; Lipscomb J; Mitchell J; Khalil G; Garcia-Lerma G; Heneine W
J Infect Dis; 2018 Sep; 218(8):1284-1290. PubMed ID: 29788316
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
13. Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
Tsegaye TS; Butler K; Luo W; Radzio J; Srinivasan P; Sharma S; Aubert RD; Hanson DL; Dobard C; Garcia-Lerma JG; Heneine W; McNicholl JM; Kersh EN
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):385-94. PubMed ID: 25886925
[TBL] [Abstract][Full Text] [Related]
14. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
15. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF
J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibody-mediated protection against simian-HIV infection among macaques with vaginal sexually transmitted infections.
Garber DA; Guenthner P; Zhao C; Mitchell J; Ellis S; Jia H; Manganare M; Gazumyan A; Seaman MS; Vishwanathan SA; Heneine W; McNicholl JM
AIDS; 2023 Apr; 37(5):723-731. PubMed ID: 36625252
[TBL] [Abstract][Full Text] [Related]
18. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
19. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
[TBL] [Abstract][Full Text] [Related]
20. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques.
Vishwanathan SA; Zhao C; Luthra R; Khalil GK; Morris MM; Dinh C; Gary MJ; Mitchell J; Spreen WR; Pereira LE; Heneine W; García-Lerma JG; McNicholl JM
AIDS; 2022 Feb; 36(2):169-176. PubMed ID: 34482355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
